Lefisyo (Levomethadone Hydrochloride)

Levomethadone Hydrochloride works by fully activating μ‑opioid receptors, which produces analgesia and reduces cravings in opioid‑dependent individuals. It also blocks NMDA receptors, a mechanism that can lessen the development of opioid tolerance and may improve pain control.

The specific dose of Lefisyo is determined by the prescribing clinician based on the patient’s medical condition, prior opioid exposure, and response to therapy. Dosing regimens are individualized and should follow local prescribing guidelines and the prescriber’s judgment.

Safety data for levomethadone hydrochloride in pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against possible risks and discuss any concerns with the patient. Use during pregnancy or while breastfeeding should only occur under direct medical supervision.

To request Lefisyo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with methadone, levomethadone is the levorotatory isomer and may have a slightly different side‑effect profile, while still providing full μ‑opioid agonism. Unlike buprenorphine, it is a full agonist rather than a partial agonist, which can result in stronger analgesia but also a higher risk of respiratory depression if not carefully monitored.

Lefisyo should be stored at ambient temperature below 25 °C, in its original packaging, protected from moisture, light, and excessive heat. Keep the product out of reach of children and do not use it after the expiration date.

Lefisyo is taken orally as directed by a qualified prescriber. The tablet (or other oral dosage form) is swallowed whole with water, and dosing intervals are determined by the treating clinician based on the individual’s therapeutic needs.

The most serious risks include respiratory depression, especially when therapy is initiated or when combined with other CNS depressants, QT‑interval prolongation that can lead to cardiac arrhythmias, severe hypotension, and the potential for physical dependence or addiction if misused.

Lefisyo is contraindicated in patients with known hypersensitivity to levomethadone or any component of the formulation, in individuals with severe respiratory insufficiency, uncontrolled asthma, or acute narrow‑angle glaucoma, and in patients currently taking monoamine oxidase inhibitors without an appropriate wash‑out period.